查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1457961

医疗外骨骼的全球市场：市场规模和占有率分析（依组件、类型和肢体）-工业需求预测（截至 2030 年）

Medical Exoskeleton Market Size and Share Analysis by Component (Hardware, Software), Type (Powered, Passive), Extremity (Upper Extremities, Lower Extremities, Full Body) - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球医疗外骨骼市场规模将达4.858亿美元，2030年将达63.368亿美元，复合年增长率为44.8%。

该行业的成长主要得益于残疾人数量的快速增加、老年人口的增加以及骨科手术数量的增加。

北美引领世界市场

北美将在 2023 年成为最大的市场，占据 55% 的占有率，并在未来几年取得巨大进步。 这是由于老年人口快速成长、政府对外骨骼的支持力度加大、神经系统疾病发生率上升。

由于医疗保健资金增加、最近的产品批准以及需要行动和康復支持的患者数量不断增加，亚太地区正在以最快的速度取得进展。

依细分市场分析

依组件划分，硬体类别将于 2023 年以 60% 的占有率引领行业，并在未来几年以 45.0% 的复合年增长率增长。 这是因为外骨骼是使用不同的硬体製造的，例如电力系统、感测器、控制系统和执行器。

依类型划分，由于最近的改进，功率类型占有很大占有率。

在四肢方面，下肢外骨骼在2023年占据领先地位。 这可能是由于下半身区域疾病的盛行率增加，包括脚踝、脚、膝盖和臀部。

本报告分析了全球医疗外骨骼市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、依地区和主要国家的市场规模前景（金额（基数、 2017-2030），依组件、类型和肢体划分的详细趋势、当前市场竞争状况以及主要公司概况。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

  • 市场动态
    • 趋势
    • 促进因素
    • 抑制因素/课题
    • 促进/抑制因子影响分析
  • 新型冠状病毒感染 (COVID-19) 的影响
  • 波特五力分析

第六章世界市场

  • 摘要
  • 市场收入：依组成部分划分（2017-2030 年）
  • 市场收入：依类型划分（2017-2030 年）
  • 市场收入：依肢体分类（2017-2030 年）
  • 市场收入：依地区划分（2017-2030 年）

第七章北美市场

  • 摘要
  • 市场收入：依组成部分划分（2017-2030 年）
  • 市场收入：依类型划分（2017-2030 年）
  • 市场收入：依肢体分类（2017-2030 年）
  • 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

  • 摘要
  • 市场收入：依组成部分划分（2017-2030 年）
  • 市场收入：依类型划分（2017-2030 年）
  • 市场收入：依肢体分类（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

  • 市场参与者及其提供的产品/服务的列表
  • 主要公司的竞争基准
  • 各大公司的产品基准
  • 近期策略发展状况

第30章公司简介

  • Ekso Bionics Holdings Inc.
  • ReWalk Robotics Ltd.
  • Parker-Hannifin Corporation
  • BIONIK Laboratories Corp.
  • Rex Bionics Ltd.
  • B-Temia Inc.
  • Bioventus LLC
  • Hocoma AG

第31章附录

简介目录
Product Code: 12787

The medical exoskeleton market generated a value of USD 485.8 million in 2023, which will increase to USD 6,336.8 million, with a 44.8% CAGR, by 2030.

The growth of this industry is mainly because of the surging count of people with physical disabilities, the increasing elderly population, and the rising number of orthopedic surgeries.

For instance, as per the World Health Organization, an estimated 1.3 billion individuals, or 1 out of 6 people globally, experience significant disability.

Moreover, as per the United Nations, the number of people who are 65 years and above is rising at a faster rate compared to those below this age. Also, the percentage of the worldwide population aged 65 and above is likely to reach 16% in 2050 from 10% in 2022.

Furthermore, more than 300 million orthopedic operations are performed across the globe every year, 75% of which take place in developed nations.

In addition, the surging number of road accidents, strokes, and severe injuries, is also aiding the expansion of this industry. The WHO says that around 1.3 million people die annually because of road traffic crashes. Therefore, the rising acceptance of medical exoskeletons for the curing of injuries is boosting industry expansion.

North America Leading the Global Market

North America was the largest contributor to the industry in 2023, with a 55% share, and it will advance significantly in the coming years. This is because of the surging elderly population, rising government support for exoskeletons, and high incidence of neurological ailments.

For example, Human in Motion Robotics Inc. (HMR), in September 2022, declared a CAD 663,000 contract from Innovative Solutions Canada for the Department of National Defence Canada.

The contract is for the Canadian government to buy HMR's next-generation lower-extremity exoskeleton, XoMotion, which is intended to remove people's reliance on wheelchairs and enable them total mobility.

APAC is advancing at the fastest rate, owing to the increasing funding in healthcare, recent product approvals, and a growing patient pool requiring mobility and rehabilitation support.

Segmentation Analysis

The hardware category, based on component, led the industry in 2023, with a 60% share, and it will propel at a 45.0% CAGR in the coming years. This can be because exoskeletons are produced using different pieces of hardware, such as powered systems, sensors, control systems, and actuators.

The powered category, based on type, was the larger contributor to the industry, owing to the recent improvements in them. For example, Stanford University, with investment from the NIH, has developed an exoskeleton that rapidly adapts to users' movement while they walk normally.

Additionally, major players in this industry are concentrating on incorporating cutting-edge technologies like AI, to improve their product performance. AI increases the human potential, along with the efficiency of the devices.

In 2023, lower-extremity exoskeletons led the extremity category. This can be credited to the increasing prevalence of lower body parts disability, including the ankles, feet, and knee & hip joints.

Competitive Landscape

Businesses are concentrating on partnerships & acquisitions:

In November 2021, Ottobock declared the acquisition of 100% shares of suitX, a U.S.-based business spun out of the Robotics & Human Engineering Lab at the University of California, which is mostly involved in medical exoskeletons R&D.

In April 2022, Blackrock Neurotech declared that it will partner for R&D with Phantom Neuro for its patent-pending Phantom X system.

With the rising number of people with physical disabilities across the globe, the medical exoskeleton industry will continue to grow in the coming years.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by component
    • 1.4.2. Market size breakdown, by type
    • 1.4.3. Market size breakdown, by extremity
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Component (2017-2030)
  • 6.3. Market Revenue, by Type (2017-2030)
  • 6.4. Market Revenue, by Extremity (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Component (2017-2030)
  • 7.3. Market Revenue, by Type (2017-2030)
  • 7.4. Market Revenue, by Extremity (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Component (2017-2030)
  • 8.3. Market Revenue, by Type (2017-2030)
  • 8.4. Market Revenue, by Extremity (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Component (2017-2030)
  • 9.3. Market Revenue, by Type (2017-2030)
  • 9.4. Market Revenue, by Extremity (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Component (2017-2030)
  • 10.3. Market Revenue, by Type (2017-2030)
  • 10.4. Market Revenue, by Extremity (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Component (2017-2030)
  • 11.3. Market Revenue, by Type (2017-2030)
  • 11.4. Market Revenue, by Extremity (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Component (2017-2030)
  • 12.3. Market Revenue, by Type (2017-2030)
  • 12.4. Market Revenue, by Extremity (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Component (2017-2030)
  • 13.3. Market Revenue, by Type (2017-2030)
  • 13.4. Market Revenue, by Extremity (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Component (2017-2030)
  • 14.3. Market Revenue, by Type (2017-2030)
  • 14.4. Market Revenue, by Extremity (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Component (2017-2030)
  • 15.3. Market Revenue, by Type (2017-2030)
  • 15.4. Market Revenue, by Extremity (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Component (2017-2030)
  • 16.3. Market Revenue, by Type (2017-2030)
  • 16.4. Market Revenue, by Extremity (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Component (2017-2030)
  • 17.3. Market Revenue, by Type (2017-2030)
  • 17.4. Market Revenue, by Extremity (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Component (2017-2030)
  • 18.3. Market Revenue, by Type (2017-2030)
  • 18.4. Market Revenue, by Extremity (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Component (2017-2030)
  • 19.3. Market Revenue, by Type (2017-2030)
  • 19.4. Market Revenue, by Extremity (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Component (2017-2030)
  • 20.3. Market Revenue, by Type (2017-2030)
  • 20.4. Market Revenue, by Extremity (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Component (2017-2030)
  • 21.3. Market Revenue, by Type (2017-2030)
  • 21.4. Market Revenue, by Extremity (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Component (2017-2030)
  • 22.3. Market Revenue, by Type (2017-2030)
  • 22.4. Market Revenue, by Extremity (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Component (2017-2030)
  • 23.3. Market Revenue, by Type (2017-2030)
  • 23.4. Market Revenue, by Extremity (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Component (2017-2030)
  • 24.3. Market Revenue, by Type (2017-2030)
  • 24.4. Market Revenue, by Extremity (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Component (2017-2030)
  • 25.3. Market Revenue, by Type (2017-2030)
  • 25.4. Market Revenue, by Extremity (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Component (2017-2030)
  • 26.3. Market Revenue, by Type (2017-2030)
  • 26.4. Market Revenue, by Extremity (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Component (2017-2030)
  • 27.3. Market Revenue, by Type (2017-2030)
  • 27.4. Market Revenue, by Extremity (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Component (2017-2030)
  • 28.3. Market Revenue, by Type (2017-2030)
  • 28.4. Market Revenue, by Extremity (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. Ekso Bionics Holdings Inc.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. ReWalk Robotics Ltd.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Parker-Hannifin Corporation
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. BIONIK Laboratories Corp.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Rex Bionics Ltd.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. B-Temia Inc.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Bioventus LLC
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Hocoma AG
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports